Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy
TOPLINE:In a first in-human study, KITE-363, an anti-CD19/CD2src chimeric antigen receptor (CAR) T-cell therapy, showed high rates of response in...
TOPLINE:In a first in-human study, KITE-363, an anti-CD19/CD2src chimeric antigen receptor (CAR) T-cell therapy, showed high rates of response in...